Company profile

Geoffrey Straub Martha
Fiscal year end
Former names
Medtronic Holdings Ltd, Medtronic Ltd

MDT stock data



19 Jun 20
12 Jul 20
24 Apr 21


Company financial data Financial data

Quarter (USD) Apr 20 Jan 20 Oct 19 Jul 19
Revenue 6B 7.72B 7.71B 7.49B
Net income 640M 1.92B 1.37B 877M
Diluted EPS 0.48 1.42 1.01 0.64
Net profit margin 10.67% 24.87% 17.79% 11.70%
Operating income 316M 1.64B 1.35B 1.49B
Net change in cash 431M -253M -1.12B 687M
Cash on hand 4.14B 3.71B 3.96B 5.08B
Cost of revenue 2.26B 2.4B 2.39B 2.37B
Annual (USD) Apr 20 Apr 19 Apr 18 Apr 17
Revenue 28.91B 30.56B 29.95B 29.71B
Net income 4.81B 4.65B 3.1B 4.02B
Diluted EPS 3.54 3.41 2.27 2.89
Net profit margin 16.62% 15.22% 10.33% 13.54%
Operating income 4.79B 6.27B 6.64B 5.38B
Net change in cash -253M 724M -1.3B 2.09B
Cash on hand 4.14B 4.39B 3.67B 4.97B
Cost of revenue 9.42B 9.16B 9.07B 9.29B

Financial data from Medtronic earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
30 Jun 20 Omar Ishrak Ordinary Shares Gift Aquire G No 0 22,508 0 22,508
30 Jun 20 Omar Ishrak Ordinary Shares Gift Dispose G No 0 22,508 0 584,989
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Aquire G No 0 305 0 605
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Dispose G No 0 305 0 85,110
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Aquire G No 0 305 0 605
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Dispose G No 0 305 0 85,415
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Aquire G No 0 305 0 605
1 Jun 20 Parkhill Karen L Ordinary Shares Gift Dispose G No 0 305 0 85,720
29 May 20 Surface Carol A Ordinary Shares Sell Dispose S No 97.72 2,000 195.44K 47,443
29 Apr 20 Anderson Richard H Ordinary Shares Payment of exercise Dispose F No 99.14 393 38.96K 96,881
80.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1632 1688 -3.3%
Opened positions 132 239 -44.8%
Closed positions 188 76 +147.4%
Increased positions 735 683 +7.6%
Reduced positions 601 563 +6.7%
13F shares
Current Prev Q Change
Total value 97.2B 124.85B -22.1%
Total shares 1.08B 1.1B -2.1%
Total puts 5.17M 6.21M -16.8%
Total calls 8.76M 7.23M +21.2%
Total put/call ratio 0.6 0.9 -31.4%
Largest owners
Shares Value Change
Vanguard 117.74M $10.62B +2.7%
BLK BlackRock 106.86M $9.64B -2.5%
Wellington Management 67.27M $6.07B -2.2%
STT State Street 58.3M $5.29B +0.8%
Massachusetts Financial Services 52.78M $4.76B -0.4%
Lazard Asset Management 25.7M $2.32B -10.5%
BAC Bank of America 21.5M $1.94B +4.2%
Geode Capital Management 20.33M $1.83B +3.2%
AMP Ameriprise Financial 19.03M $1.72B +7.3%
BEN Franklin Resources 18.47M $1.67B +1.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -14.53M EXIT
Vanguard 117.74M +3.12M +2.7%
Lazard Asset Management 25.7M -3.02M -10.5%
N Price T Rowe Associates 16.38M -2.81M -14.6%
BLK BlackRock 106.86M -2.7M -2.5%
Primecap Management 2.66M -2.31M -46.5%
FRLG Goldman Sachs 5.98M -2.1M -26.0%
Boston Partners 6.42M -1.88M -22.7%
FIL 714.86K -1.87M -72.3%
Amundi Pioneer Asset Management 7.38M -1.59M -17.8%

Financial report summary

  • The novel coronavirus disease 2019 (COVID-19) has had, and we expect will continue to have, an adverse effect on our business, results of operations, financial condition and cash flows, the nature and extent of which are highly uncertain and unpredictable.
  • We operate in a highly competitive industry and we may be unable to compete effectively.
  • Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.
  • We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
  • Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition and cash flows.
  • We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.
  • Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.
  • Healthcare policy changes may have a material adverse effect on us.
  • Our insurance program may not be adequate to cover future losses.
  • If we experience decreasing prices for our goods and services and we are unable to reduce our expenses, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.
  • The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.
  • Laws and regulations governing international business operations could adversely impact our business.
  • Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
  • Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.
  • We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.
  • The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.
  • Our substantial leverage and debt service obligations could adversely affect our business.
  • Failure to integrate acquired businesses into our operations successfully, as well as liabilities or claims relating to such acquired businesses, could adversely affect our business.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.
  • The Medtronic, Inc. tax court proceeding outcome could have a material adverse impact on our financial condition.
  • Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S federal income tax purposes.
  • Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.
  • We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.
  • As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit Medtronic’s flexibility to manage its capital structure.
  • A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.
  • In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.
  • Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.
Content analysis ?
H.S. freshman Avg
New words: abolished, AI, air, alter, American, ample, annum, appendectomy, atrioventricular, attestation, Autoguide, AV, bariatric, bear, Bennet, brainsense, Brett, CABG, Chinese, Chrome, circular, cleaning, Cobalt, compelled, COREX, CP, CR, Crome, curtailment, deferrable, deferral, deleveraging, deprioritize, deprioritized, digital, Dissector, drafted, dramatically, drill, DTM, ECMO, economy, EEA, Envision, escalating, extracorporeal, factory, freezing, GPA, halted, hemorrhagic, hysterectomy, implicit, inbound, induce, insolvency, intelligence, job, lender, lesser, lessor, macroeconomic, MDR, Medtrconic, Mizuho, Moderately, multicurrency, multiplexed, NaN, NMPA, occupancy, oncology, outlined, Pacifica, Paclitaxel, pandemic, parameter, Pathway, play, port, postpone, postponed, precautionary, preferential, prioritize, prioritized, quarantine, reliance, reprioritization, respectfully, resumption, resurgence, retaliation, RGR, rm, run, Salmon, Sean, shelf, SI, slowdown, spread, staffing, Station, straining, Strastosphere, Stratosphere, stronger, SVP, tariff, TAVR, team, Tech, thrown, TIBOR, timetable, Titan, titanium, top, travel, turn, twelve, undrawn, unemployment, unprecedented, unsuccessful, urgent, waveform, Yuan
Removed: accelerate, Aerospace, allegedly, applying, Ardian, authorizing, bedside, British, CAPSTONE, Captivia, Cardio, career, CareLink, certified, charitable, clarify, coil, complaint, composed, condensed, confirmed, correspondingly, defibrillation, denied, disallowance, distributable, earliest, enforcing, EPS, Eritrea, existence, expandable, expend, faster, finalize, flu, fulfill, Hakami, Hooman, HVAD, iDrive, incision, incurring, insufficiently, joint, Labour, launching, left, liquidate, Methodist, Ministry, misleading, MVAD, noted, Ontario, Oximeter, Paul, portable, realigned, reconstruction, redeem, referendum, relationship, rental, reorganize, repatriated, resolving, retrospectively, Salient, season, separation, Signia, Similarly, slight, steady, subsequently, summarizing, trademark, Transformation, transformative, undertook, unfavorably, unissued, unqualified, Valtech, VERTEX, violated, VISION, wholly, yrs